Uncategorized

Uncategorized

Moehs Group at the Pharmaceutical Manufacturing Catskills Training 2024

On 15th of November, Moehs Group team had the pleasure of collaborating in the Pharmaceutical Manufacturing Catskills 2024 training, organized at INS La Romànica, in Barberà del Vallès. A day full of learning for all participants, who worked on the manufacture of an ibuprofen suspension for children, demonstrating the talent and dedication of future professionals […]

Moehs Group at the Pharmaceutical Manufacturing Catskills Training 2024 Read More »

Moehs Group and EUROAPI sign an exclusive agreement for the production of Metamizole in Europe.

Moehs Group, a leading international group in the production of active pharmaceutical ingredients, has signed an exclusive agreement with EUROAPI to take over the production of Metamizole, the active ingredient of Nolotil, at its facilities in Spain. This exclusive agreement between Moehs Group and EUROAPI aims to complete the evaluation of the technical transfer of

Moehs Group and EUROAPI sign an exclusive agreement for the production of Metamizole in Europe. Read More »

CO2 EMISSION SAVINGS

At Moehs Group we are very committed to caring for our planet and our activity strictly complies with each and every one of our commitments. With regard to our project to mitigate greenhouse gases, we have expanded the number of photovoltaic installations during the first semester of 2024. Between January and June 2024, the current

CO2 EMISSION SAVINGS Read More »

2 GRANTS FROM CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN

The Administration Board of the Centro para el Desarrollo Tecnológico y la Innovación, E.P.E (CDTI), has approved 2 important grants for Moehs Group: ABROCITINIB: development of a new chemical synthesis method of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis. VERICIGUAT: the objective is to develop a new method of chemical

2 GRANTS FROM CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN Read More »